ClinicalTrials.gov
ClinicalTrials.gov Menu

Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma (PEXIUS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01632826
Expanded Access Status : Approved for marketing
First Posted : July 3, 2012
Last Update Posted : April 25, 2017
Sponsor:
Information provided by (Responsible Party):
Celgene

No Study Results Posted on ClinicalTrials.gov for this Study
  Expanded Access Status : Approved for marketing
  Primary Completion Date : No date given
  Study Completion Date : No date given